NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Galectin Therapeutics Inc. (GALT) Stock Analysis

Galectin Therapeutics Inc. (GALT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GALT

$4.61

+$0.26 (+5.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GALT with… →

GALT Key Statistics

As of Sep 4, 2026
Trading
Open
$4.33
Previous Close
$4.35
Day's Range
4.33–4.72
52-Week Range
2.03–7.13
Volume
473.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.39
Valuation
Market Cap
$464.92M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−36.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.46
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$30.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.85M
1-Year Return
−1.28%
Dividend and dates
Avg Volume
648.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GALT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.82%
2025+222.48%
2024−22.29%
2023+46.90%
2022−45.41%
2021−7.59%
2020−21.68%
2019−16.62%
2018+2.69%
2017+240.82%
2016 (partial year)−54.63%

As of September 4, 2026.

GALT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$30.84M—
2024$0.00−$47.05M—
2023$0.00−$41.07M—
2022$0.00−$38.78M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.09M−$30.84M—
2024$0.00—−$42.43M−$47.05M—
2023$0.00—−$38.07M−$41.07M—
2022$0.00—−$38.35M−$38.78M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GALT Valuation vs Biotechnology Median

Median of 656 stocks
MetricGALTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Galectin Therapeutics Inc. (GALT) is capitalised at $464.92M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 9 employees.

The most recent close on file for GALT is $4.61, dated September 4, 2026. That is +$0.26 (+5.98%) against the previous close. The 52-week range on file runs from $2.03 to $7.13. The latest close sits 127.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $30.84M. The reported profit margin is 0%. Trailing earnings per share are −0.46.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads −36.15.

Over the trailing twelve months the price has returned −1.28%. Across 10 years the annualized return works out at +10.49%. Beta against the wider market is reported at 0.39. Daily returns over the trailing 10 years annualize to a volatility of 94%.

Growth & Income

No dividend is on file for GALT.

Across the complete calendar years on file, 2017 returned +240.82% and 2022 returned −45.41%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +10.82%.

Peer Comparison

Galectin Therapeutics Inc. (GALT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Galectin Therapeutics Inc. GALT $464.92M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Galectin Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Visit website →